Signs of STD

"sti chlamydia" - Google News

Get link
Facebook
X
Pinterest
Email
Other Apps

September 27, 2025

[unable to retrieve full-text content]

Why Syphilis Cases in Newborns Are Rising Even as STIs Decline  Time Magazine

Get link
Facebook
X
Pinterest
Email
Other Apps

Comments

Letter: No gag rule - Anchorage Daily News

March 31, 2019

Letter: No gag rule Anchorage Daily News I fear for the future. What kind of helpful information will my son receive from his health care providers — if any?

Senior citizens are getting STDs at historic high levels - WTRF

February 26, 2020

Senior citizens are getting STDs at historic high levels WTRF

Clark County Ranks First in Nation in Syphilis Rates - U.S. News & World Report

April 28, 2019

Clark County Ranks First in Nation in Syphilis Rates U.S. News & World Report LAS VEGAS (AP) — Southern Nevada consistently ranks high for STD rates, but health officials are stepping up public education campaigns as Clark County ...

Powered by Blogger

Theme images by Michael Elkan

"signs for hiv infection" - Google News

August 22, 2025

[unable to retrieve full-text content] A Timeline of HIV Symptoms: How Does It Progress?    Healthline

Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More - Yahoo Finance

December 30, 2022

The biotech sector was in focus with many important pipeline and regulatory updates. Collaboration deals were also in focus. Recap of the Week's Most Important Stories : Gilead's HIV Drug Approval :  Gilead Sciences, Inc . GILD announced that the FDA has approved lenacapavir in combination with other antiretroviral(s) (ARV) under the brand name Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug-resistant (MDR) HIV-1 infection. The approval of this new, twice-yearly treatment option for adults with HIV that is not adequately controlled by their current treatment regimen will boost Gilead's strong HIV franchise. Sunlenca, a first-in-class, long-acting HIV capsid inhibitor, has a multi-stage mechanism of action distinguishable from other currently approved classes of antiviral agents.  It is the only HIV treatment option administered twice yearly and thus will have an advantage over other existing treat...